The challenges and prospects of running oncology trials are set to be dissected at the upcoming 10th Annual Clinical Trials in Oncology Europe 2023 conference that will take place later 28-29 November. The meeting will be held in Munich, Germany.
Opening with a talk on the impact of new technology on oncology clinical studies, the first day of the conference will cover recent advances and innovations. These include technologies like eConsent, interactive response technology (IRT) and electronic clinical outcome assessment (eCOA), and how they can be used for a more streamlined trial experience. The discussions will not only highlight the ways such innovations can benefit trial sponsors, but also the clinical teams. This will be followed by further talks covering the improvements in real-world data and evidence integration and trends in complex exploratory studies, improving patient collaboration in oncology trials.
The first day will also host a larger panel that will feature experts from Alligator Bioscience and BeiGene discussing the key functions needed to reduce study start-up time and how to bring drugs to market faster.
Continuing into the conference’s second day, the event will open up with roundtable sessions to share best practice insights into key issues facing the industry. This includes a roundtable on improving patient enrolment in new trials hosted by speaker Sumeet Ambarkhane, the chief medical officer of Alligator Bioscience, and another one on patient diversity in cancer trials.
The second day will also feature two talks that will discuss how smaller biotechs can select CROs. Hosted by Robert Dobosz, Ryvu Therapeutics’ director of clinical trials solutions, the second talk will also delve into what small biotechs need to bear in mind to make sure they safely proceed with contracts.
Near the close of the second day, the conference will also host a talk on the impact of in vitro diagnostics (IVD) regulation changes on early-stage clinical trials hosted by Malte Oppermann, senior director of clinical operations at MediGene.
The conference is hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology.
